BioCentury
ARTICLE | Clinical News

Effient prasugrel: Phase II data

November 23, 2009 8:00 AM UTC

Data from the double-blind, crossover Phase II OPTIMUS-3 trial in 35 patients with Type II diabetes and CAD who were also taking aspirin showed that Effient significantly increased IPA vs. Plavix clopidogrel at 4 hours post-loading dose (89% vs. 28%, p<0.0001), 1 hour post-loading dose (50% vs. 13%, p<0.0001), 24 hours post-loading dose (87% vs. 29%, p<0.0001) and at 24 hours post-maintenance dose (62% vs. 44%, p<0.0001). Patients received Effient (60 mg loading dose followed by a 10 mg maintenance dose 24 hours later) or Plavix (600 mg loading dose followed by a 150 mg maintenance dose 24 hours later) followed by a 14-day washout period before receiving the other drug. Data were presented at the American Heart Association meeting in Orlando. ...